 | • レポートコード：MRC23Q35859 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、82ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界の不整脈治療市場について調査・分析し、世界の不整脈治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（ナトリウムチャネル遮断薬、ベータ遮断薬、カリウムチャネル遮断薬、カルシウムチャネル遮断薬、その他）、用途別セグメント分析（病院、診療所、その他）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Mylan N.V.、Teva Pharmaceutical Industries Ltd、Pfizer Inc、Sanofi、Upsher-Smith Laboratories, LLC、Covis Pharma、Novartis AG、Mayne Pharma Group Limited、Eli Lilly and Companyなどが含まれています。 世界の不整脈治療市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、不整脈治療市場規模を推定する際に考慮しました。本レポートは、不整脈治療の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、不整脈治療に関するビジネス上の意思決定に役立てることを目的としています。 ・不整脈治療市場の概要 - 不整脈治療のタイプ別セグメント - 世界の不整脈治療市場規模：タイプ別分析（ナトリウムチャネル遮断薬、ベータ遮断薬、カリウムチャネル遮断薬、カルシウムチャネル遮断薬、その他） - 不整脈治療の用途別セグメント - 世界の不整脈治療市場規模：用途別分析（病院、診療所、その他） - 世界の不整脈治療市場規模予測（2018年-2029年） ・不整脈治療市場の成長トレンド - 不整脈治療の地域別市場規模（2018年-2029年） - 不整脈治療市場ダイナミクス - 不整脈治療の業界動向 - 不整脈治療市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：ナトリウムチャネル遮断薬、ベータ遮断薬、カリウムチャネル遮断薬、カルシウムチャネル遮断薬、その他 - 世界の不整脈治療のタイプ別市場規模（2018年-2023年） - 世界の不整脈治療のタイプ別市場規模（2024年-2029年） ・用途別セグメント：病院、診療所、その他 - 世界の不整脈治療の用途別市場規模（2018年-2023年） - 世界の不整脈治療の用途別市場規模（2024年-2029年） ・不整脈治療の地域別市場規模 - 北米の不整脈治療市場規模（2018年-2029年） - アメリカの不整脈治療市場規模（2018年-2029年） - ヨーロッパの不整脈治療市場規模（2018年-2029年） - アジア太平洋の不整脈治療市場規模（2018年-2029年） - 中国の不整脈治療市場規模（2018年-2029年） - 日本の不整脈治療市場規模（2018年-2029年） - 韓国の不整脈治療市場規模（2018年-2029年） - インドの不整脈治療市場規模（2018年-2029年） - オーストラリアの不整脈治療市場規模（2018年-2029年） - 中南米の不整脈治療市場規模（2018年-2029年） - 中東・アフリカの不整脈治療市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Mylan N.V.、Teva Pharmaceutical Industries Ltd、Pfizer Inc、Sanofi、Upsher-Smith Laboratories, LLC、Covis Pharma、Novartis AG、Mayne Pharma Group Limited、Eli Lilly and Company ・アナリストの観点/結論 ・調査方法とデータソース |
Highlights
The global Cardiac Arrhythmia Therapeutics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Cardiac Arrhythmia Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cardiac Arrhythmia Therapeutics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Cardiac Arrhythmia Therapeutics in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Cardiac Arrhythmia Therapeutics include Mylan N.V., Teva Pharmaceutical Industries Ltd, Pfizer Inc, Sanofi, Upsher-Smith Laboratories, LLC, Covis Pharma, Novartis AG, Mayne Pharma Group Limited and Eli Lilly and Company, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cardiac Arrhythmia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cardiac Arrhythmia Therapeutics.
The Cardiac Arrhythmia Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cardiac Arrhythmia Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cardiac Arrhythmia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Mylan N.V.
Teva Pharmaceutical Industries Ltd
Pfizer Inc
Sanofi
Upsher-Smith Laboratories, LLC
Covis Pharma
Novartis AG
Mayne Pharma Group Limited
Eli Lilly and Company
Segment by Type
Sodium-channel Blockers
Beta-blockers
Potassium-channel Blockers
Calcium-channel Blockers
Others
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cardiac Arrhythmia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Cardiac Arrhythmia Therapeutics Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Sodium-channel Blockers
1.2.3 Beta-blockers
1.2.4 Potassium-channel Blockers
1.2.5 Calcium-channel Blockers
1.2.6 Others
1.3 Market by Application
1.3.1 Global Cardiac Arrhythmia Therapeutics Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cardiac Arrhythmia Therapeutics Market Perspective (2018-2029)
2.2 Cardiac Arrhythmia Therapeutics Growth Trends by Region
2.2.1 Global Cardiac Arrhythmia Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cardiac Arrhythmia Therapeutics Historic Market Size by Region (2018-2023)
2.2.3 Cardiac Arrhythmia Therapeutics Forecasted Market Size by Region (2024-2029)
2.3 Cardiac Arrhythmia Therapeutics Market Dynamics
2.3.1 Cardiac Arrhythmia Therapeutics Industry Trends
2.3.2 Cardiac Arrhythmia Therapeutics Market Drivers
2.3.3 Cardiac Arrhythmia Therapeutics Market Challenges
2.3.4 Cardiac Arrhythmia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cardiac Arrhythmia Therapeutics Players by Revenue
3.1.1 Global Top Cardiac Arrhythmia Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Cardiac Arrhythmia Therapeutics Revenue Market Share by Players (2018-2023)
3.2 Global Cardiac Arrhythmia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cardiac Arrhythmia Therapeutics Revenue
3.4 Global Cardiac Arrhythmia Therapeutics Market Concentration Ratio
3.4.1 Global Cardiac Arrhythmia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cardiac Arrhythmia Therapeutics Revenue in 2022
3.5 Cardiac Arrhythmia Therapeutics Key Players Head office and Area Served
3.6 Key Players Cardiac Arrhythmia Therapeutics Product Solution and Service
3.7 Date of Enter into Cardiac Arrhythmia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Cardiac Arrhythmia Therapeutics Breakdown Data by Type
4.1 Global Cardiac Arrhythmia Therapeutics Historic Market Size by Type (2018-2023)
4.2 Global Cardiac Arrhythmia Therapeutics Forecasted Market Size by Type (2024-2029)
5 Cardiac Arrhythmia Therapeutics Breakdown Data by Application
5.1 Global Cardiac Arrhythmia Therapeutics Historic Market Size by Application (2018-2023)
5.2 Global Cardiac Arrhythmia Therapeutics Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Cardiac Arrhythmia Therapeutics Market Size (2018-2029)
6.2 North America Cardiac Arrhythmia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cardiac Arrhythmia Therapeutics Market Size by Country (2018-2023)
6.4 North America Cardiac Arrhythmia Therapeutics Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cardiac Arrhythmia Therapeutics Market Size (2018-2029)
7.2 Europe Cardiac Arrhythmia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cardiac Arrhythmia Therapeutics Market Size by Country (2018-2023)
7.4 Europe Cardiac Arrhythmia Therapeutics Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cardiac Arrhythmia Therapeutics Market Size (2018-2029)
8.2 Asia-Pacific Cardiac Arrhythmia Therapeutics Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cardiac Arrhythmia Therapeutics Market Size by Region (2018-2023)
8.4 Asia-Pacific Cardiac Arrhythmia Therapeutics Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cardiac Arrhythmia Therapeutics Market Size (2018-2029)
9.2 Latin America Cardiac Arrhythmia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cardiac Arrhythmia Therapeutics Market Size by Country (2018-2023)
9.4 Latin America Cardiac Arrhythmia Therapeutics Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cardiac Arrhythmia Therapeutics Market Size (2018-2029)
10.2 Middle East & Africa Cardiac Arrhythmia Therapeutics Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cardiac Arrhythmia Therapeutics Market Size by Country (2018-2023)
10.4 Middle East & Africa Cardiac Arrhythmia Therapeutics Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mylan N.V.
11.1.1 Mylan N.V. Company Detail
11.1.2 Mylan N.V. Business Overview
11.1.3 Mylan N.V. Cardiac Arrhythmia Therapeutics Introduction
11.1.4 Mylan N.V. Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.1.5 Mylan N.V. Recent Development
11.2 Teva Pharmaceutical Industries Ltd
11.2.1 Teva Pharmaceutical Industries Ltd Company Detail
11.2.2 Teva Pharmaceutical Industries Ltd Business Overview
11.2.3 Teva Pharmaceutical Industries Ltd Cardiac Arrhythmia Therapeutics Introduction
11.2.4 Teva Pharmaceutical Industries Ltd Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.2.5 Teva Pharmaceutical Industries Ltd Recent Development
11.3 Pfizer Inc
11.3.1 Pfizer Inc Company Detail
11.3.2 Pfizer Inc Business Overview
11.3.3 Pfizer Inc Cardiac Arrhythmia Therapeutics Introduction
11.3.4 Pfizer Inc Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.3.5 Pfizer Inc Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Cardiac Arrhythmia Therapeutics Introduction
11.4.4 Sanofi Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.4.5 Sanofi Recent Development
11.5 Upsher-Smith Laboratories, LLC
11.5.1 Upsher-Smith Laboratories, LLC Company Detail
11.5.2 Upsher-Smith Laboratories, LLC Business Overview
11.5.3 Upsher-Smith Laboratories, LLC Cardiac Arrhythmia Therapeutics Introduction
11.5.4 Upsher-Smith Laboratories, LLC Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.5.5 Upsher-Smith Laboratories, LLC Recent Development
11.6 Covis Pharma
11.6.1 Covis Pharma Company Detail
11.6.2 Covis Pharma Business Overview
11.6.3 Covis Pharma Cardiac Arrhythmia Therapeutics Introduction
11.6.4 Covis Pharma Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.6.5 Covis Pharma Recent Development
11.7 Novartis AG
11.7.1 Novartis AG Company Detail
11.7.2 Novartis AG Business Overview
11.7.3 Novartis AG Cardiac Arrhythmia Therapeutics Introduction
11.7.4 Novartis AG Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.7.5 Novartis AG Recent Development
11.8 Mayne Pharma Group Limited
11.8.1 Mayne Pharma Group Limited Company Detail
11.8.2 Mayne Pharma Group Limited Business Overview
11.8.3 Mayne Pharma Group Limited Cardiac Arrhythmia Therapeutics Introduction
11.8.4 Mayne Pharma Group Limited Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.8.5 Mayne Pharma Group Limited Recent Development
11.9 Eli Lilly and Company
11.9.1 Eli Lilly and Company Company Detail
11.9.2 Eli Lilly and Company Business Overview
11.9.3 Eli Lilly and Company Cardiac Arrhythmia Therapeutics Introduction
11.9.4 Eli Lilly and Company Revenue in Cardiac Arrhythmia Therapeutics Business (2018-2023)
11.9.5 Eli Lilly and Company Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details